RBC lowers the target price for TRL to 2.00. I don't think their target price is interesting. Trimel will go much much higher if and when Compleo is approved and Tefine generates positive phase II b results. However, it shows that RBC is convinced that the FDA will approve Compleo. Otherwise, their target price would have been much lower than 2.00. 

http://www.i3investor.com/servlets/fdnews/162239.jsp